Literature DB >> 7539799

A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26).

J S Duke-Cohan1, C Morimoto, J A Rocker, S F Schlossman.   

Abstract

Human CD26, a Type II membrane glycoprotein with intrinsic dipeptidylpeptidase IV (DPPIV) activity and ability to bind adenosine deaminase type I (ADA-1), is expressed on epithelial cells constitutively, but on T lymphocytes its expression is regulated. A soluble form of CD26/DPPIV has been described in plasma and related to immunological status, but it has been defined by the presence of DPPIV activity rather than by isolation. Using nondenaturing chromatographic techniques followed by nondenaturing native preparative electrophoresis, we obtained a homogeneous preparation of soluble serum DPPIV and compared it with a recombinant soluble CD26/DPPIV (rsCD26). We show that serum DPPIV is a monomer of 175 kDa in contrast to rsCD26 of 105-110 kDa, that it exists as a trimer, and that it is probably a serine proteinase. Deglycosylation removed N-linked sugar from both serum DPPIV and rsCD26; no O-linked glycosylation was observed, revealing a protein core of 130 kDa for serum DPPIV. The large serum form expresses functional DPPIV activity with substrate and inhibitor specificities and pH activity profile similar to those of rsCD26. Epitope analysis showed that monoclonal antibodies against five epitopes expressed by rsCD26 also bound, but more weakly, with serum DPPIV. Analysis of peptides after limiting proteolysis and N-terminal sequences reveals no homology with rsCD26 but some identity with other peptidases. Unlike rsCD26, the serum form does not bind ADA-1 and has no ADA-1 already associated with it. Similarly to rsCD26, serum DPPIV is a potent T cell costimulator. We conclude that the serum form of DPPIV is unique and is not a breakdown product of membrane CD26. The conservation of DPPIV activity and five epitopes specific to rsCD26 suggest, however, a significant structural similarity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539799     DOI: 10.1074/jbc.270.23.14107

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Research advances in metabolism 2016.

Authors:  Nikolaos Perakakis; Olivia M Farr; Dario Tuccinardi; Jagriti Upadhyay; Christos S Mantzoros
Journal:  Metabolism       Date:  2016-11-06       Impact factor: 8.694

2.  Multicolor cytoenzymatic evaluation of dipeptidyl peptidase IV (CD26) function in normal and neoplastic human T-lymphocyte populations.

Authors:  P Ruiz; N Zacharievich; M Shenkin
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

3.  Cloning and functional expression of rat kidney dipeptidyl peptidase II.

Authors:  K M Fukasawa; K Fukasawa; K Higaki; N Shiina; M Ohno; S Ito; J Otogoto; N Ota
Journal:  Biochem J       Date:  2001-01-15       Impact factor: 3.857

4.  Attractin (DPPT-L), a member of the CUB family of cell adhesion and guidance proteins, is secreted by activated human T lymphocytes and modulates immune cell interactions.

Authors:  J S Duke-Cohan; J Gu; D F McLaughlin; Y Xu; G J Freeman; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

5.  Potential of soluble CD26 as a serum marker for colorectal cancer detection.

Authors:  Oscar J Cordero; Monica Imbernon; Loretta De Chiara; Vicenta S Martinez-Zorzano; Daniel Ayude; Maria Paez de la Cadena; F Javier Rodriguez-Berrocal
Journal:  World J Clin Oncol       Date:  2011-06-10

6.  Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes.

Authors:  Bilal A Omar; Liu Liehua; Yuchiro Yamada; Yutaka Seino; Piero Marchetti; B Ahrén
Journal:  Diabetologia       Date:  2014-06-18       Impact factor: 10.122

7.  Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent.

Authors:  Adolfo Varona; Lorena Blanco; Itxaro Perez; Javier Gil; Jon Irazusta; José I López; M Luz Candenas; Francisco M Pinto; Gorka Larrinaga
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

8.  Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis.

Authors:  Y N Williams; H Baba; S Hayashi; H Ikai; T Sugita; S Tanaka; N Miyasaka; T Kubota
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

9.  Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Tamyra D Downs; Patrick A McKee
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

10.  Defective surface expression of attractin on T cells in patients with common variable immunodeficiency (CVID).

Authors:  N Pozzi; L Gaetaniello; B Martire; D De Mattia; B Balestrieri; E Cosentini; S F Schlossman; J S Duke-Cohan; C Pignata
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.